U.S. Entertainment Stock News

SpaceX’s post IPO slide, from a market value above $2.6 trillion to about $1.72 trillion within days, has sent a clear message to anyone watching new listings closely. When a flagship space stock stumbles after listing and short sellers walk away with an estimated $3.9 billion, it can rattle confidence well beyond one ticker. This article looks at three stocks exposed to the same news shock, each facing its own version of post debut volatility risk. You will see where the pressure points are...

Middle East oil routes are being redrawn as the Strait of Hormuz closure disrupts Iraq’s exports and pushes governments and energy majors to rethink how crude leaves the region. For investors, this shift is less about short term headlines and more about which stocks are directly exposed to the surge in pipeline construction, oilfield services and security heavy infrastructure projects tied to new export corridors through Iraq and Syria. This article walks through 3 stocks linked to that news,...

Keros Therapeutics, Inc.'s (NASDAQ:KROS) stock price has dropped 12% in the previous week, but insiders who sold...

FormFactor stock has delivered a very strong 3 year return and is still up sharply over the past year, yet the valuation checks currently lean expensive rather than pointing to an obvious bargain. FormFactor has returned 207.5% over the past 3 years, which puts extra focus on whether today’s price still offers a comfortable margin for error. AI driven demand for high bandwidth memory and related chip testing can support optimistic expectations, but recent concerns about overvaluation and...

Timken stock has almost doubled over the past five years, and at around US$137.69 per share the Discounted Cash Flow (DCF) intrinsic value estimate still points to roughly 20.3% upside, even though the broader valuation checks only give the company a low score. Timken has returned about 95.9% over five years, which puts today’s valuation debate in the context of a stock that has already rewarded long term holders. The newly secured US$1.2b unsecured revolving credit facility can support...

Delta Air Lines, Inc.'s ( NYSE:DAL ) recent weak earnings report didn't cause a big stock movement. However, we believe...

We wouldn't blame Covista Inc. ( NYSE:CVSA ) shareholders if they were a little worried about the fact that Stephen...

While QuickLogic Corporation ( NASDAQ:QUIK ) might not have the largest market cap around , it received a lot of...

BlackRock (BLK) just posted its Q2 2026 numbers, reporting total revenue of US$7.1 billion, basic EPS of US$12.33 and trailing twelve month EPS of US$42.40. Trailing twelve month revenue stands at US$27.3 billion and net income at US$6.6 billion. The company’s revenue has moved from US$24.2 billion on a trailing basis in Q4 2025 to US$27.3 billion in Q2 2026. Over the same period, trailing EPS shifted from US$35.83 to US$42.40. This context helps frame how investors evaluate Q2 profitability...

The Morning Bull - US Market Morning Update Friday, Jul, 17 2026 US stock futures are slightly weaker this morning, with S&P 500 contracts down about 0.1%, as investors weigh softer US producer price data against higher bond yields and fresh trade tensions. June producer prices fell 0.3% month on month while core prices, which strip out food and energy, rose 0.2%, suggesting that factory level inflation is easing even as the cost of services inches higher. At the same time, the 10 year...

Critical Metals (CRML) has begun a broad review of its portfolio after appointing advisers to explore asset sales, joint ventures, and partnerships, with the aim of channeling more capital toward its Tanbreez rare earth project in Greenland. See our latest analysis for Critical Metals. The strategic review comes after a sharp pullback in Critical Metals' recent share price, with the stock down 10.17% on a 1 day basis, 20.78% over 7 days, and 46.58% over 90 days, even as the 1 year total...

Prosperity Bancshares has returned 33.3% over the past three years, and today the stock trades at US$74.73. Both the Excess Returns intrinsic value estimate and earnings multiples suggest it may be undervalued, even as competition in its core Texas markets intensifies and recent analyst views have turned more cautious. A 33.3% three year return points to steady shareholder gains that set a higher bar for any further upside to be justified by fundamentals. Recent acquisitions and a shift...

Adams Diversified Equity Fund has delivered a strong 122.1% total return over the past 5 years, yet current valuation checks and market multiples still point to the stock as screening on the cheaper side rather than obviously priced for perfection. A 122.1% return over 5 years suggests that long term holders in Adams Diversified Equity Fund have already seen substantial value created, which raises the bar for any further upside to be justified by fundamentals. Recent coverage highlighting...

J.B. Hunt Transport Services (JBHT) has reported Q2 2026 revenue of US$3.5 billion and basic EPS of US$1.91, against a backdrop where earnings over the last year are reported to have grown 21.8%. The company’s quarterly revenue has increased from US$2,928.2 million and EPS of US$1.32 in Q2 2025 to US$3,495.3 million and EPS of US$1.91 in Q2 2026. Over the same period, trailing net margin has moved up to 5.3% from 4.6% in the prior year. These shifts may encourage investors to examine how the...

Danaher stock sits in an unusual valuation spot right now, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a meaningful discount, while earnings-based multiples lean the other way and flag the shares as expensive. Over the past 5 years, Danaher shares have declined 18%, which means long-term holders have not yet seen a clear payoff from staying invested. Recent news around Leica Biosystems’ planned acquisition of StatLab and new Alzheimer’s testing capabilities at...

Hasbro, ticker NasdaqGS:HAS, and Nintendo have agreed a multi year licensing partnership to produce The Legend of Zelda toys. The toy line is scheduled to launch in 2027 alongside the planned live action The Legend of Zelda film. The agreement extends Hasbro's relationship with Nintendo beyond existing franchises and adds a new entertainment linked product range. Hasbro has been building out its position in branded toys, games and collectibles, and this new Zelda partnership is part of...

SharonAI Holdings has delivered a very large 1 year return, yet its valuation checks and current market multiples point to a stock that leans expensive rather than clearly cheap. Over the last 12 months, SharonAI Holdings has returned about 7.7x, which puts extra pressure on today’s price to be backed by durable cash flow and earnings quality. Expectations that the company can translate its business model into consistent, scalable cash generation may support the current share price. However,...

Stereotaxis (STXS) recently filed two shelf registrations that together cover up to about $205.3 million of common equity, highlighting potential future capital raises that could affect dilution and investor sentiment toward the stock. See our latest analysis for Stereotaxis. The recent shelf registrations arrive during a weaker patch for Stereotaxis, with the stock closing at US$1.65 and recording a 30 day share price return down 9.34%, alongside a 1 year total shareholder return down 30.67%...

In July 2026, Silo Communications in Illinois and Oso Internet Solutions on the Ramah Navajo Reservation each announced that they are deploying ADTRAN Holdings’ fiber access platforms, Mosaic software and in-home gateways to extend high-speed broadband into underserved rural and remote communities. These rural deployments highlight ADTRAN Holdings’ growing role as a partner for publicly backed broadband expansion, where scalable fiber and software-driven automation are critical for reaching...

West Pharmaceutical Services has delivered a 64.1% return over the past year, and after that kind of run the stock no longer looks obviously cheap, especially with most of the valuation checks leaning toward a premium price tag. The Discounted Cash Flow (DCF) intrinsic value estimate points to a roughly fair valuation, while market based multiples suggest the shares are priced on the rich side. West Pharmaceutical Services' 64.1% 1 year return puts recent momentum front and center, which can...

With Dallas Fed President Lorie Logan arguing that current interest rates are still not tight enough to pull inflation back to 2%, many risk-heavy stocks could feel the pressure as the market braces for potential policy surprises at the late July FOMC meeting. Short duration fixed income related companies sit in a different part of the market, where cash flows are often tied to shorter term instruments that can reset more quickly. This article looks at 3 stocks from a Short-Duration Fixed...

With stock valuations stretched, margin debt at extremes and IPO activity setting records, many investors are rethinking how much risk they really want to carry. Defensive dividend stocks can offer a different way to stay invested, focusing on established businesses with steady income rather than fast growth stories that depend heavily on market optimism. This article looks at how these market signals might affect a selection of defensive dividend payers, and highlights 3 stocks from our...

Karooooo (NasdaqCM:KARO) opened Q1 2027 with revenue of ZAR1.6b and basic EPS of ZAR9.53, setting a clear benchmark for how the company is currently converting its top line into per share earnings. Over recent periods, the company has reported revenue of ZAR1.3b in Q1 2026 and ZAR1.6b in Q1 2027, while basic EPS has ranged from ZAR8.55 in Q1 2026 to ZAR9.53 in the latest quarter. This gives investors a clear view of how revenue and per share earnings have moved together. With margins now in...

QuidelOrtho (QDEL) is back in focus after filing a shelf registration for up to 1,000,000 shares of common stock. This ESOP-related move puts potential equity issuance on investors' radar. See our latest analysis for QuidelOrtho. At a share price of US$18.24, QuidelOrtho has seen a 30-day share price return of 29.18% and a 90-day share price return of 43.51%, yet the year-to-date share price return is down 36.62% and the 3-year total shareholder return has declined 78.49%. This suggests that...